Latest Industry Insights
Meet the Scientists Bringing Back the Extinct Tasmanian Tiger
The biotech/genetic engineering company Colossal – co-founded in 2021 by renowned geneticist Professor George Church and serial entrepreneur Ben Lamm – announced it has begun a de-extinction project of the thylacine – an Australian marsupial commonly referred to as the “Tasmanian tiger”. Technology Networks interviewed the team to learn more.
Broadening the Adoption of Pharmacogenomic Testing
Technology Networks recently had the pleasure of speaking to Dr. Philip Empey, to learn more about the Pharmacogenomics Center for Excellence and how it is working to prove the clinical utility of predictive PGx testing.
A New Approach to T-Cell Therapy
In this interview with Bryan Kobel, CEO of TC Biopharm, we find out about gamma-delta T-cell therapy, including how it works, its applications and how TC Biopharm developed its pioneering gamma-delta treatment for acute myeloid leukemia.
Novel Biosensor Aims To Help Fight Against Forever Chemicals
There is widespread concern about the characteristics of PFAS and its impacts on human health. Can a protein biosensor help in this fight?
Machine Learning Helps Achieve Greater Depth in Proteome Analysis
To understand how machine learning methods and new software capabilities are helping proteomics researchers gain greater depth in their analyses, Technology Networks recently interviewed Tharan Srikumar, product manager in bioinformatics at Bruker Daltonics.
A Paradigm Shift in Sepsis Diagnostics
In this interview, Rolland Carlson, PhD, CEO of Immunexpress, discusses sepsis and the company’s FDA cleared SeptiCyte® RAPID test, as well as a take on the company’s differentiated value and outlook.
Exploring Flow Electroporation for Cell Engineering
Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.
Developing Therapeutics To Combat ALS
In this interview, we speak to Alon Ben-Noon, CEO and co-founder of Neurosense Therapeutics to hear about the impact their drug development strategy is having on the ALS field.
Exploring the Ethical Challenges of Brain–Computer Interface Technology
This article explores the current state of brain-computer interface technology and some of the ethical considerations associated with its use.
New Technology Aims To Accelerate Biopharma Development
Developing and manufacturing biotherapeutics at scale requires thorough analysis of the active substance’s characteristics to ensure it fulfils both efficacy and safety requirements. Analytical technologies, such as mass spectrometry, are key tools adopted in this process.